Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein

Jayne F. Koellhoffer, Gang Chen, Rohini G. Sandesara, Shridhar Bale, Erica Ollmann Saphire, Kartik Chandran, Sachdev S. Sidhu, Jonathan R. Lai

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Ebola virus (EBOV) is a highly pathogenic member of the Filoviridae family of viruses that causes severe hemorrhagic fever. Infection proceeds through fusion of the host cell and viral membranes, a process that is mediated by the viral envelope glycoprotein (GP). Following endosomal uptake, a key step in viral entry is the proteolytic cleavage of GP by host endosomal cysteine proteases. Cleavage exposes a binding site for the host cell receptor Niemann-Pick C1 (NPC1) and may induce conformational changes in GP leading to membrane fusion. However, the precise details of the structural changes in GP associated with proteolysis and the role of these changes in viral entry have not been established. Here, we have employed synthetic antibody technology to identify antibodies targeting EBOV GP prior to and following proteolysis (i.e. in the "uncleaved" [GPUNCL] and "cleaved" [GPCL] forms). We identified antibodies with distinct recognition profiles: FabCL bound preferentially to GPCL (EC50=1.7 nM), whereas FabUNCL bound specifically to GPUNCL (EC50=75 nM). Neutralization assays with GP-containing pseudotyped viruses indicated that these antibodies inhibited GPCL- or GPUNCL-mediated viral entry with specificity matching their recognition profiles (IC50: 87 nM for IgGCL; 1 μM for FabUNCL). Competition ELISAs indicate that FabCL binds an epitope distinct from that of KZ52, a well-characterized EBOV GP antibody, and from that of the luminal domain of NPC1. The binding epitope of FabUNCL was also distinct from that of KZ52, suggesting that FabUNCL binds a novel neutralization epitope on GPUNCL. Furthermore, the neutralizing ability of FabCL suggests that there are targets on GPCL available for neutralization. This work showcases the applicability of synthetic antibody technology to the study of viral membrane fusion, and provides new tools for dissecting intermediates of EBOV entry.

Original languageEnglish (US)
Pages (from-to)2549-2557
Number of pages9
JournalChemBioChem
Volume13
Issue number17
DOIs
StatePublished - Nov 2012

Fingerprint

Viruses
Glycoproteins
Ebolavirus
Antibodies
Proteolysis
Epitopes
Virus Internalization
Fusion reactions
Membranes
Filoviridae
Technology
Membrane Fusion
Cysteine Proteases
Ebola virus envelope glycoprotein
Inhibitory Concentration 50
Assays
Fever
Enzyme-Linked Immunosorbent Assay
Binding Sites
Cell Membrane

Keywords

  • Antibody engineering
  • Ebola virus
  • Filovirus
  • Phage display
  • Synthetic antibodies
  • Viral membrane fusion

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein. / Koellhoffer, Jayne F.; Chen, Gang; Sandesara, Rohini G.; Bale, Shridhar; Ollmann Saphire, Erica; Chandran, Kartik; Sidhu, Sachdev S.; Lai, Jonathan R.

In: ChemBioChem, Vol. 13, No. 17, 11.2012, p. 2549-2557.

Research output: Contribution to journalArticle

Koellhoffer, Jayne F. ; Chen, Gang ; Sandesara, Rohini G. ; Bale, Shridhar ; Ollmann Saphire, Erica ; Chandran, Kartik ; Sidhu, Sachdev S. ; Lai, Jonathan R. / Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein. In: ChemBioChem. 2012 ; Vol. 13, No. 17. pp. 2549-2557.
@article{883d630cc62d46b89b9e236b9db2b8be,
title = "Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein",
abstract = "Ebola virus (EBOV) is a highly pathogenic member of the Filoviridae family of viruses that causes severe hemorrhagic fever. Infection proceeds through fusion of the host cell and viral membranes, a process that is mediated by the viral envelope glycoprotein (GP). Following endosomal uptake, a key step in viral entry is the proteolytic cleavage of GP by host endosomal cysteine proteases. Cleavage exposes a binding site for the host cell receptor Niemann-Pick C1 (NPC1) and may induce conformational changes in GP leading to membrane fusion. However, the precise details of the structural changes in GP associated with proteolysis and the role of these changes in viral entry have not been established. Here, we have employed synthetic antibody technology to identify antibodies targeting EBOV GP prior to and following proteolysis (i.e. in the {"}uncleaved{"} [GPUNCL] and {"}cleaved{"} [GPCL] forms). We identified antibodies with distinct recognition profiles: FabCL bound preferentially to GPCL (EC50=1.7 nM), whereas FabUNCL bound specifically to GPUNCL (EC50=75 nM). Neutralization assays with GP-containing pseudotyped viruses indicated that these antibodies inhibited GPCL- or GPUNCL-mediated viral entry with specificity matching their recognition profiles (IC50: 87 nM for IgGCL; 1 μM for FabUNCL). Competition ELISAs indicate that FabCL binds an epitope distinct from that of KZ52, a well-characterized EBOV GP antibody, and from that of the luminal domain of NPC1. The binding epitope of FabUNCL was also distinct from that of KZ52, suggesting that FabUNCL binds a novel neutralization epitope on GPUNCL. Furthermore, the neutralizing ability of FabCL suggests that there are targets on GPCL available for neutralization. This work showcases the applicability of synthetic antibody technology to the study of viral membrane fusion, and provides new tools for dissecting intermediates of EBOV entry.",
keywords = "Antibody engineering, Ebola virus, Filovirus, Phage display, Synthetic antibodies, Viral membrane fusion",
author = "Koellhoffer, {Jayne F.} and Gang Chen and Sandesara, {Rohini G.} and Shridhar Bale and {Ollmann Saphire}, Erica and Kartik Chandran and Sidhu, {Sachdev S.} and Lai, {Jonathan R.}",
year = "2012",
month = "11",
doi = "10.1002/cbic.201200493",
language = "English (US)",
volume = "13",
pages = "2549--2557",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "Wiley-VCH Verlag",
number = "17",

}

TY - JOUR

T1 - Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein

AU - Koellhoffer, Jayne F.

AU - Chen, Gang

AU - Sandesara, Rohini G.

AU - Bale, Shridhar

AU - Ollmann Saphire, Erica

AU - Chandran, Kartik

AU - Sidhu, Sachdev S.

AU - Lai, Jonathan R.

PY - 2012/11

Y1 - 2012/11

N2 - Ebola virus (EBOV) is a highly pathogenic member of the Filoviridae family of viruses that causes severe hemorrhagic fever. Infection proceeds through fusion of the host cell and viral membranes, a process that is mediated by the viral envelope glycoprotein (GP). Following endosomal uptake, a key step in viral entry is the proteolytic cleavage of GP by host endosomal cysteine proteases. Cleavage exposes a binding site for the host cell receptor Niemann-Pick C1 (NPC1) and may induce conformational changes in GP leading to membrane fusion. However, the precise details of the structural changes in GP associated with proteolysis and the role of these changes in viral entry have not been established. Here, we have employed synthetic antibody technology to identify antibodies targeting EBOV GP prior to and following proteolysis (i.e. in the "uncleaved" [GPUNCL] and "cleaved" [GPCL] forms). We identified antibodies with distinct recognition profiles: FabCL bound preferentially to GPCL (EC50=1.7 nM), whereas FabUNCL bound specifically to GPUNCL (EC50=75 nM). Neutralization assays with GP-containing pseudotyped viruses indicated that these antibodies inhibited GPCL- or GPUNCL-mediated viral entry with specificity matching their recognition profiles (IC50: 87 nM for IgGCL; 1 μM for FabUNCL). Competition ELISAs indicate that FabCL binds an epitope distinct from that of KZ52, a well-characterized EBOV GP antibody, and from that of the luminal domain of NPC1. The binding epitope of FabUNCL was also distinct from that of KZ52, suggesting that FabUNCL binds a novel neutralization epitope on GPUNCL. Furthermore, the neutralizing ability of FabCL suggests that there are targets on GPCL available for neutralization. This work showcases the applicability of synthetic antibody technology to the study of viral membrane fusion, and provides new tools for dissecting intermediates of EBOV entry.

AB - Ebola virus (EBOV) is a highly pathogenic member of the Filoviridae family of viruses that causes severe hemorrhagic fever. Infection proceeds through fusion of the host cell and viral membranes, a process that is mediated by the viral envelope glycoprotein (GP). Following endosomal uptake, a key step in viral entry is the proteolytic cleavage of GP by host endosomal cysteine proteases. Cleavage exposes a binding site for the host cell receptor Niemann-Pick C1 (NPC1) and may induce conformational changes in GP leading to membrane fusion. However, the precise details of the structural changes in GP associated with proteolysis and the role of these changes in viral entry have not been established. Here, we have employed synthetic antibody technology to identify antibodies targeting EBOV GP prior to and following proteolysis (i.e. in the "uncleaved" [GPUNCL] and "cleaved" [GPCL] forms). We identified antibodies with distinct recognition profiles: FabCL bound preferentially to GPCL (EC50=1.7 nM), whereas FabUNCL bound specifically to GPUNCL (EC50=75 nM). Neutralization assays with GP-containing pseudotyped viruses indicated that these antibodies inhibited GPCL- or GPUNCL-mediated viral entry with specificity matching their recognition profiles (IC50: 87 nM for IgGCL; 1 μM for FabUNCL). Competition ELISAs indicate that FabCL binds an epitope distinct from that of KZ52, a well-characterized EBOV GP antibody, and from that of the luminal domain of NPC1. The binding epitope of FabUNCL was also distinct from that of KZ52, suggesting that FabUNCL binds a novel neutralization epitope on GPUNCL. Furthermore, the neutralizing ability of FabCL suggests that there are targets on GPCL available for neutralization. This work showcases the applicability of synthetic antibody technology to the study of viral membrane fusion, and provides new tools for dissecting intermediates of EBOV entry.

KW - Antibody engineering

KW - Ebola virus

KW - Filovirus

KW - Phage display

KW - Synthetic antibodies

KW - Viral membrane fusion

UR - http://www.scopus.com/inward/record.url?scp=84869465815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869465815&partnerID=8YFLogxK

U2 - 10.1002/cbic.201200493

DO - 10.1002/cbic.201200493

M3 - Article

C2 - 23111988

AN - SCOPUS:84869465815

VL - 13

SP - 2549

EP - 2557

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

IS - 17

ER -